Reflux Disease Therapy in the Management of Childhood Asthma-data Entry and Analysis Only
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
There have been a number of studies which attribute causality between reflux disease and asthma. In addition, clinicians typically treat chronic asthmatics with high dose acid suppressing medications (e.g. lansoprazole). However, clinical trials only recently have shed some light on this dilemma, with recent studies suggesting that the association is not as clear. This "retrospective" analysis of a prospective study which treated mod-severe asthmatics with lansoprazole or placebo will enter the collected raw data into a database, then perform statistical analyses to determine if children with asthma treated with acid suppression improved their asthma compared to those receiving placebo.
Asthma exacerbations in the treatment group [ Time Frame: Over 21 months ]
This is a retrospective study. We will be entering data collected in a prospective clinical trial and then analyzing such data to determine if intervention with acid suppression, lansoprazole improves the number of asthma exacerbation in a one year period compared to those receiving placebo.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
4 Years to 11 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
This is a retrospective study. The study will simply be taking data collected during a prospective study and analyzing that data. There will be no subjects enrolled in this retrospective study. The subjects enrolled in the prospective study were children, ages 4 to 11 years of age.
Patients who were enrolled in the study, "Randomized, Double-blind, Placebo Controlled Study of Gastroesophageal Reflux Disease Therapy (Lansoprazole; Solutab™) in the Management of Childhood Asthma" will be entered into this database. Only these patients will be included in this study, all other patients will be excluded.
Patients who were not enrolled in the study, "Randomized, Double-blind, Placebo Controlled Study of Gastroesophageal Reflux Disease Therapy (Lansoprazole; Solutab™) in the Management of Childhood Asthma" will not be included in this study.